OncoSignal
Indications / Non-small cell lung cancer · Breast cancer · Pancreatic cancer · Colorectal cancer · Acute myeloid leukemia · Chronic myeloid leukemia · Multiple myeloma · Glioblastoma · Glioma · Neuroblastoma · Medulloblastoma · Diffuse midline glioma (DIPG) · Ependymoma · Atypical teratoid rhabdoid tumour (AT/RT) · Childhood acute lymphoblastic leukemia · Ewing sarcoma · Osteosarcoma · Rhabdomyosarcoma

Diffuse midline glioma (DIPG)

H3 K27-altered tumours of the brainstem and midline, with no curative treatment: ONC201 and cell therapy trials.

Live from ClinicalTrials.gov + PubMed, fetched 2026-11-12 07:22 UTC. Every row links to its source record.

Principal investigators and study chairs named on the registry for diffuse midline glioma (dipg), ranked by a published score: 3 per Phase 2+ trial they lead, 1 per other trial role, 2 per oral or late-breaking talk and 0.5 per poster in our verified 2026 meeting rows, each halved every 24 months. Paper authorship is not scored yet. PubMed counts are author name plus indication, for the top 12; names are as the registry spells them, so a common name can pool several people. Open a row for their trials and links to their papers.

Maryam Fouladi
Nationwide Children's Hospital
score 4.4
40 papers
Profile: all trials, NIH grants and most cited papers →Papers in diffuse midline glioma (dipg) (PubMed)Trial papers onlyAll registered trials naming them (ClinicalTrials.gov)

Score 4.4 = 4.4 leading Phase 2+ trials + 0.1 other trial roles + 0 talks + 0 posters. 3 of 4 trials are Phase 2+.

Eric M Thompson
Washington University School of Medicine
score 4.3
5 papers
Profile: all trials, NIH grants and most cited papers →Papers in diffuse midline glioma (dipg) (PubMed)Trial papers onlyAll registered trials naming them (ClinicalTrials.gov)

Score 4.3 = 4.3 leading Phase 2+ trials + 0 other trial roles + 0 talks + 0 posters. 2 of 2 trials are Phase 2+.

Tom Davidson
Children's Hospital Los Angeles
score 3
0 papers
Profile: all trials, NIH grants and most cited papers →Papers in diffuse midline glioma (dipg) (PubMed)Trial papers onlyAll registered trials naming them (ClinicalTrials.gov)

Score 3 = 3 leading Phase 2+ trials + 0 other trial roles + 0 talks + 0 posters. 1 of 1 trials are Phase 2+.

Giselle Saulnier Sholler
Penn State Health Children's Hospital
score 2.5
0 papers
Profile: all trials, NIH grants and most cited papers →Papers in diffuse midline glioma (dipg) (PubMed)Trial papers onlyAll registered trials naming them (ClinicalTrials.gov)

Score 2.5 = 2.5 leading Phase 2+ trials + 0 other trial roles + 0 talks + 0 posters. 1 of 1 trials are Phase 2+.

Yuanyuan Chen
Sun Yat-Sen University Cancer Center
score 2.5
13 papers
Profile: all trials, NIH grants and most cited papers →Papers in diffuse midline glioma (dipg) (PubMed)Trial papers onlyAll registered trials naming them (ClinicalTrials.gov)

Score 2.5 = 2.5 leading Phase 2+ trials + 0 other trial roles + 0 talks + 0 posters. 1 of 1 trials are Phase 2+.

Margot Lazow
Nationwide Children's Hospital
score 2.2
5 papers
Profile: all trials, NIH grants and most cited papers →Papers in diffuse midline glioma (dipg) (PubMed)Trial papers onlyAll registered trials naming them (ClinicalTrials.gov)

Score 2.2 = 2.1 leading Phase 2+ trials + 0.1 other trial roles + 0 talks + 0 posters. 2 of 3 trials are Phase 2+.

David S. Ziegler
Sydney Children's Hospitals Network
score 1.9
34 papers
Profile: all trials, NIH grants and most cited papers →Papers in diffuse midline glioma (dipg) (PubMed)Trial papers onlyAll registered trials naming them (ClinicalTrials.gov)

Score 1.9 = 1.9 leading Phase 2+ trials + 0 other trial roles + 0 talks + 0 posters. 1 of 1 trials are Phase 2+.

Peter de Blank
Children's Hospital Medical Center, Cincinnati
score 1.9
0 papers
Profile: all trials, NIH grants and most cited papers →Papers in diffuse midline glioma (dipg) (PubMed)Trial papers onlyAll registered trials naming them (ClinicalTrials.gov)

Score 1.9 = 1.9 leading Phase 2+ trials + 0 other trial roles + 0 talks + 0 posters. 1 of 1 trials are Phase 2+.

Sara Khan
Nationwide Children's Hospital
score 1.9
1 papers
Profile: all trials, NIH grants and most cited papers →Papers in diffuse midline glioma (dipg) (PubMed)Trial papers onlyAll registered trials naming them (ClinicalTrials.gov)

Score 1.9 = 1.9 leading Phase 2+ trials + 0 other trial roles + 0 talks + 0 posters. 1 of 1 trials are Phase 2+.

Heather McCrea
University of Miami
score 1.8
1 papers
Profile: all trials, NIH grants and most cited papers →Papers in diffuse midline glioma (dipg) (PubMed)Trial papers onlyAll registered trials naming them (ClinicalTrials.gov)

Score 1.8 = 1.8 leading Phase 2+ trials + 0 other trial roles + 0 talks + 0 posters. 1 of 1 trials are Phase 2+.

Michael J Fisher
Children's Hospital of Philadelphia
score 1.6
1 papers
Profile: all trials, NIH grants and most cited papers →Papers in diffuse midline glioma (dipg) (PubMed)Trial papers onlyAll registered trials naming them (ClinicalTrials.gov)

Score 1.6 = 1.6 leading Phase 2+ trials + 0 other trial roles + 0 talks + 0 posters. 1 of 1 trials are Phase 2+.

Nicholas G Gottardo
Perth Children's Hospital
score 1.6
7 papers
Profile: all trials, NIH grants and most cited papers →Papers in diffuse midline glioma (dipg) (PubMed)Trial papers onlyAll registered trials naming them (ClinicalTrials.gov)

Score 1.6 = 1.6 leading Phase 2+ trials + 0 other trial roles + 0 talks + 0 posters. 1 of 1 trials are Phase 2+.

Santosh Valvi
Perth Children's Hospital
score 1.6
–
Profile: all trials, NIH grants and most cited papers →Papers in diffuse midline glioma (dipg) (PubMed)Trial papers onlyAll registered trials naming them (ClinicalTrials.gov)

Score 1.6 = 1.6 leading Phase 2+ trials + 0 other trial roles + 0 talks + 0 posters. 1 of 1 trials are Phase 2+.

Daniel Landi
Duke Cancer Center
score 1.3
–
Profile: all trials, NIH grants and most cited papers →Papers in diffuse midline glioma (dipg) (PubMed)Trial papers onlyAll registered trials naming them (ClinicalTrials.gov)

Score 1.3 = 1.3 leading Phase 2+ trials + 0 other trial roles + 0 talks + 0 posters. 1 of 1 trials are Phase 2+.

John Ligon
University of Florida
score 1
–
Profile: all trials, NIH grants and most cited papers →Papers in diffuse midline glioma (dipg) (PubMed)Trial papers onlyAll registered trials naming them (ClinicalTrials.gov)

Score 1 = 0 leading Phase 2+ trials + 1 other trial roles + 0 talks + 0 posters. 0 of 1 trials are Phase 2+.

Luca Szalontay
Children's National Research Institute
score 1
–
Profile: all trials, NIH grants and most cited papers →Papers in diffuse midline glioma (dipg) (PubMed)Trial papers onlyAll registered trials naming them (ClinicalTrials.gov)

Score 1 = 0 leading Phase 2+ trials + 1 other trial roles + 0 talks + 0 posters. 0 of 1 trials are Phase 2+.

Lung-Ji Chang
Shenzhen Geno-Immune Medical Institute
score 1
–
Profile: all trials, NIH grants and most cited papers →Papers in diffuse midline glioma (dipg) (PubMed)Trial papers onlyAll registered trials naming them (ClinicalTrials.gov)

Score 1 = 0 leading Phase 2+ trials + 1 other trial roles + 0 talks + 0 posters. 0 of 1 trials are Phase 2+.

Cori Abikoff
BrainChild Bio, Inc
score 0.9
–
Profile: all trials, NIH grants and most cited papers →Papers in diffuse midline glioma (dipg) (PubMed)Trial papers onlyAll registered trials naming them (ClinicalTrials.gov)

Score 0.9 = 0 leading Phase 2+ trials + 0.9 other trial roles + 0 talks + 0 posters. 1 of 1 trials are Phase 2+.

Josh Neman
NeOnc Technologies Holdings, Inc.
score 0.9
–
Profile: all trials, NIH grants and most cited papers →Papers in diffuse midline glioma (dipg) (PubMed)Trial papers onlyAll registered trials naming them (ClinicalTrials.gov)

Score 0.9 = 0 leading Phase 2+ trials + 0.9 other trial roles + 0 talks + 0 posters. 0 of 1 trials are Phase 2+.

Thomas Chen
NeOnc Technologies Holdings, Inc.
score 0.9
–
Profile: all trials, NIH grants and most cited papers →Papers in diffuse midline glioma (dipg) (PubMed)Trial papers onlyAll registered trials naming them (ClinicalTrials.gov)

Score 0.9 = 0 leading Phase 2+ trials + 0.9 other trial roles + 0 talks + 0 posters. 0 of 1 trials are Phase 2+.

Sabine Mueller
University of California, San Francisco
score 0.8
–
Profile: all trials, NIH grants and most cited papers →Papers in diffuse midline glioma (dipg) (PubMed)Trial papers onlyAll registered trials naming them (ClinicalTrials.gov)

Score 0.8 = 0.5 leading Phase 2+ trials + 0.3 other trial roles + 0 talks + 0 posters. 1 of 2 trials are Phase 2+.

Gregory Kane Friedman Friedman
M.D. Anderson Cancer Center
score 0.8
–
Profile: all trials, NIH grants and most cited papers →Papers in diffuse midline glioma (dipg) (PubMed)Trial papers onlyAll registered trials naming them (ClinicalTrials.gov)

Score 0.8 = 0 leading Phase 2+ trials + 0.8 other trial roles + 0 talks + 0 posters. 0 of 1 trials are Phase 2+.

Jacques GRILL
Gustave Roussy, Cancer Campus, Grand Paris
score 0.7
–
Profile: all trials, NIH grants and most cited papers →Papers in diffuse midline glioma (dipg) (PubMed)Trial papers onlyAll registered trials naming them (ClinicalTrials.gov)

Score 0.7 = 0.7 leading Phase 2+ trials + 0 other trial roles + 0 talks + 0 posters. 1 of 1 trials are Phase 2+.

Brandon Imber
Memorial Sloan Kettering Cancer Center
score 0.7
–
Profile: all trials, NIH grants and most cited papers →Papers in diffuse midline glioma (dipg) (PubMed)Trial papers onlyAll registered trials naming them (ClinicalTrials.gov)

Score 0.7 = 0 leading Phase 2+ trials + 0.7 other trial roles + 0 talks + 0 posters. 0 of 1 trials are Phase 2+.

Adam L Green
Children's Oncology Group
score 0.6
–
Profile: all trials, NIH grants and most cited papers →Papers in diffuse midline glioma (dipg) (PubMed)Trial papers onlyAll registered trials naming them (ClinicalTrials.gov)

Score 0.6 = 0.6 leading Phase 2+ trials + 0 other trial roles + 0 talks + 0 posters. 1 of 1 trials are Phase 2+.

David S Ziegler
Pediatric Early Phase Clinical Trial Network
score 0.6
–
Profile: all trials, NIH grants and most cited papers →Papers in diffuse midline glioma (dipg) (PubMed)Trial papers onlyAll registered trials naming them (ClinicalTrials.gov)

Score 0.6 = 0.6 leading Phase 2+ trials + 0 other trial roles + 0 talks + 0 posters. 1 of 1 trials are Phase 2+.

Erin K Barr
Pediatric Early Phase Clinical Trial Network
score 0.6
–
Profile: all trials, NIH grants and most cited papers →Papers in diffuse midline glioma (dipg) (PubMed)Trial papers onlyAll registered trials naming them (ClinicalTrials.gov)

Score 0.6 = 0 leading Phase 2+ trials + 0.6 other trial roles + 0 talks + 0 posters. 0 of 1 trials are Phase 2+.

Stephanie M Yoon
City of Hope Comprehensive Cancer Center LAO
score 0.6
–
Profile: all trials, NIH grants and most cited papers →Papers in diffuse midline glioma (dipg) (PubMed)Trial papers onlyAll registered trials naming them (ClinicalTrials.gov)

Score 0.6 = 0 leading Phase 2+ trials + 0.6 other trial roles + 0 talks + 0 posters. 0 of 1 trials are Phase 2+.

Tobey MacDonald
Emory University
score 0.6
–
Profile: all trials, NIH grants and most cited papers →Papers in diffuse midline glioma (dipg) (PubMed)Trial papers onlyAll registered trials naming them (ClinicalTrials.gov)

Score 0.6 = 0 leading Phase 2+ trials + 0.6 other trial roles + 0 talks + 0 posters. 0 of 1 trials are Phase 2+.

Roman O. Kowalchuk
Mayo Clinic in Rochester
score 0.5
–
Profile: all trials, NIH grants and most cited papers →Papers in diffuse midline glioma (dipg) (PubMed)Trial papers onlyAll registered trials naming them (ClinicalTrials.gov)

Score 0.5 = 0.5 leading Phase 2+ trials + 0 other trial roles + 0 talks + 0 posters. 1 of 1 trials are Phase 2+.

Zwi N Berneman
Antwerp University Hospital, Division of Hematology and Center for Cell Therapy and Regenerative Medicine
score 0.5
–
Profile: all trials, NIH grants and most cited papers →Papers in diffuse midline glioma (dipg) (PubMed)Trial papers onlyAll registered trials naming them (ClinicalTrials.gov)

Score 0.5 = 0.5 leading Phase 2+ trials + 0 other trial roles + 0 talks + 0 posters. 1 of 1 trials are Phase 2+.

Rebecca Ronsley
Seattle Children's Hospital
score 0.4
–
Profile: all trials, NIH grants and most cited papers →Papers in diffuse midline glioma (dipg) (PubMed)Trial papers onlyAll registered trials naming them (ClinicalTrials.gov)

Score 0.4 = 0 leading Phase 2+ trials + 0.4 other trial roles + 0 talks + 0 posters. 0 of 2 trials are Phase 2+.

Theodore S Johnson
Augusta University
score 0.3
–
Profile: all trials, NIH grants and most cited papers →Papers in diffuse midline glioma (dipg) (PubMed)Trial papers onlyAll registered trials naming them (ClinicalTrials.gov)

Score 0.3 = 0.3 leading Phase 2+ trials + 0 other trial roles + 0 talks + 0 posters. 1 of 1 trials are Phase 2+.

Christopher DeRenzo
St. Jude Children's Research Hospital
score 0.3
–
Profile: all trials, NIH grants and most cited papers →Papers in diffuse midline glioma (dipg) (PubMed)Trial papers onlyAll registered trials naming them (ClinicalTrials.gov)

Score 0.3 = 0 leading Phase 2+ trials + 0.3 other trial roles + 0 talks + 0 posters. 0 of 1 trials are Phase 2+.

Giedre Krenciute
St. Jude Children's Research Hospital
score 0.3
–
Profile: all trials, NIH grants and most cited papers →Papers in diffuse midline glioma (dipg) (PubMed)Trial papers onlyAll registered trials naming them (ClinicalTrials.gov)

Score 0.3 = 0 leading Phase 2+ trials + 0.3 other trial roles + 0 talks + 0 posters. 0 of 1 trials are Phase 2+.

Hideho Okada
University of California, San Francisco
score 0.3
–
Profile: all trials, NIH grants and most cited papers →Papers in diffuse midline glioma (dipg) (PubMed)Trial papers onlyAll registered trials naming them (ClinicalTrials.gov)

Score 0.3 = 0 leading Phase 2+ trials + 0.3 other trial roles + 0 talks + 0 posters. 0 of 1 trials are Phase 2+.

Kelsey Bertrand
St. Jude Children's Research Hospital
score 0.3
–
Profile: all trials, NIH grants and most cited papers →Papers in diffuse midline glioma (dipg) (PubMed)Trial papers onlyAll registered trials naming them (ClinicalTrials.gov)

Score 0.3 = 0 leading Phase 2+ trials + 0.3 other trial roles + 0 talks + 0 posters. 0 of 1 trials are Phase 2+.

Michael Platten
German Cancer Research Center Germany
score 0.3
–
Profile: all trials, NIH grants and most cited papers →Papers in diffuse midline glioma (dipg) (PubMed)Trial papers onlyAll registered trials naming them (ClinicalTrials.gov)

Score 0.3 = 0 leading Phase 2+ trials + 0.3 other trial roles + 0 talks + 0 posters. 0 of 1 trials are Phase 2+.

Sadhana Jackson
National Cancer Institute (NCI)
score 0.3
–
Profile: all trials, NIH grants and most cited papers →Papers in diffuse midline glioma (dipg) (PubMed)Trial papers onlyAll registered trials naming them (ClinicalTrials.gov)

Score 0.3 = 0 leading Phase 2+ trials + 0.3 other trial roles + 0 talks + 0 posters. 0 of 1 trials are Phase 2+.

Stergios Zacharoulis
Columbia University
score 0.3
–
Profile: all trials, NIH grants and most cited papers →Papers in diffuse midline glioma (dipg) (PubMed)Trial papers onlyAll registered trials naming them (ClinicalTrials.gov)

Score 0.3 = 0 leading Phase 2+ trials + 0.3 other trial roles + 0 talks + 0 posters. 0 of 1 trials are Phase 2+.